CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Quick facts
Phase 3 pipeline
- HD1916 · Diabetes
HD1916 is a small molecule drug that targets the SGLT2 receptor. - Omalizumab for injection · Immunology
Omalizumab is a monoclonal antibody that targets the IgE molecule, preventing it from binding to its receptor on mast cells and basophils. - Placebo of CM326
This is a placebo control arm and contains no active pharmaceutical ingredient. - SYN008 · Oncology
SYN008 is a monoclonal antibody targeting PD-1. - TG103 · Oncology
TG103 is a tyrosine kinase inhibitor that targets specific oncogenic pathways in cancer cells.
Phase 2 pipeline
- Dulaglutide,QW · Diabetes
GLP-1 receptor agonist - TG103,Q2W
- TG103,QW
Phase 1 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: